-
Mashup Score: 0
In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel. #ASH22 #FL #lymsm | @LMU_Muenchen https://t.co/U5Dw7HWMIc
-
-
Mashup Score: 0Challenging Cases in Relapsed/Refractory Follicular Lymphoma - 1 year(s) ago
The last 12 months have brought many FDA approvals, withdrawals, and updates to the field of follicular lymphoma (FL) treatment. Are you up to date?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🖥️ The last 12 months have brought many #FDA approvals, withdrawals, and updates to the field of follicular #lymphoma treatment. Are you up to date? #FL #MedEd #CME #MedTwitter #OncTwitter ➡️ https://t.co/PbkYVwKt28 https://t.co/8knRtLgk3A
-
-
Mashup Score: 1Mosunetuzumab Elicits High Remission Rates in Relapsed/Refractory Follicular Lymphoma - 2 year(s) ago
High objective response and complete response rates observed with mosunetuzumab in patients with relapsed/refractory follicular lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
High objective response and complete response rates observed with mosunetuzumab in patients with relapsed/refractory follicular lymphoma. #lymsm #FL https://t.co/PAWWJVTUFj
-
-
Mashup Score: 1
The last 12 months have brought many FDA approvals, withdrawals, and updates to the field of follicular lymphoma (FL) treatment. Are you up to date?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
❗ The last 12 months have brought many #FDA approvals, withdrawals, & updates to the field of follicular #lymphoma treatment. Are you up to date? #OncTwitter #FL #MedEd #MedTwitter ➡️ https://t.co/IY6Zd4kiBa https://t.co/dZuDnPXnQy
-
-
Mashup Score: 1
The last 12 months have brought many FDA approvals, withdrawals, and updates to the field of follicular lymphoma (FL) treatment. Are you up to date?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
❗ The last 12 months have brought many #FDA approvals, withdrawals, and updates to the field of follicular #lymphoma treatment. Are you up to date? #OncTwitter #FL #MedEd #MedTwitter ➡️ https://t.co/wWTDUde3Nw https://t.co/W60UT30idW
-
-
Mashup Score: 1FDA Grants Priority Review to Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma - 2 year(s) ago
The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has accepted the submission of a BLA for mosunetuzumab and granted it priority review for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies. #FL #lymsm https://t.co/BkRCfOlh8H
-
-
Mashup Score: 1Axicabtagene ciloleucel receives EC approval as a third-line treatment of follicular lymphoma - 2 year(s) ago
On June 28, 2022, it was announced that the European Commission (EC) has granted approval to axicabtagene ciloleucel (axi-cel), a CD19-directed chimeric antigen receptor T-cell product, for the treatment of relapsed or refractory follicular lymphoma in adult patients who have already received ≥3 lines of systemic therapy. The approval is based on key data obtained from the pivotal phase II ZUMA-5…
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 N E W S 🚨 Axicabtagene ciloleucel receives @EU_Commission approval as a fourth-line treatment of relapsed/refractory follicular lymphoma 👉 https://t.co/Zf5M95sDrI 👈 #mednews #lymsm #FL https://t.co/oKjCkj5WKu
-
-
Mashup Score: 0Axicabtagene ciloleucel receives EC approval as a third-line treatment of follicular lymphoma - 2 year(s) ago
On June 28, 2022, it was announced that the European Commission (EC) has granted approval to axicabtagene ciloleucel (axi-cel), a CD19-directed chimeric antigen receptor T-cell product, for the treatment of relapsed or refractory follicular lymphoma in adult patients who have already received ≥3 lines of systemic therapy. The approval is based on key data obtained from the pivotal phase II ZUMA-5…
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 N E W S 🚨 Axicabtagene ciloleucel receives @EU_Commission approval as a third-line treatment of relapsed/refractory follicular lymphoma 👉 https://t.co/Zf5M95sDrI 👈 #mednews #lymsm #FL https://t.co/zVgufnlRua
-
-
Mashup Score: 6Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma - 2 year(s) ago
Key Points. There is a high degree of variability and suboptimal response to available treatments for relapsed or refractory follicular lymphomaZUMA-5 (axicabta
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🗝️KEY POINTS ▪️High degree of variability and suboptimal response to available treatments for R/R follicular #lymphoma ▪️ZUMA-5 demonstrated substantially improved clinical outcomes relative to these existing therapeutic options 👉 https://t.co/2ZlPUOkWja 👈 #FL #lymsm https://t.co/ILyphTr1Pc
-
ICYMI: In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the #FDA approval of #mosunetuzumab for the treatment of relapsed or refractory follicular #lymphoma. #FL #lymsm https://t.co/stIRn8Bp59